Hyperprolactinemia is responsible for 20 to 25% of consultations of secondary amenorrhea and 17% for female infertility. Dopamine agonists are the gold standard treatment of hyperprolactinemia. Although they are associated with various adverse effects, cabergoline is generally preferred due to better compliance, limited side effects and good therapeutic response. However, bromocriptine is widely and satisfactorily used in a context of limited availability of cabergoline. We sought to describe clinical manifestations of hyperprolactinemia and response to cabergoline in a sub Saharan Africa (SSA) setting. We describe the profile of all patients with a diagnosis of hyperprolactinaemia from 1 st July 2012 to 15 th May 2014 at the Endocrinology Department of Yaoundé Central Hospital. Patients with physiological hyperprolactinemia were not considered. All patients were routinely started on cabergoline at 0.5mg/week or at 1mg/week in case of macroprolactinoma or desire to become pregnant. The duration of follow up was 8-16 months. After three months of treatment, 8 of 10 patients with amenorrhea had menses and serum prolactin levels decreased significantly at month 2-3 (p = 0.025). In conclusion, our study suggests that cabergoline yields an excellent therapeutic response in a short period of time and may thus be cost saving in sub Saharan context despite its unit price.
Introduction
Hyperprolactinemia is one of the most frequent disorders of the pituitary gland. It is responsible for 20 to 25% of consultations of secondary amenorrhea [1] and 17% for female infertility [2] , and can be caused by physiological, pharmacological or pathologic factors.
Clinical presentations of hyperprolactinemia vary with study populations and depends on the etiology hence its profiling in different populations is necessary [3] . There is paucity of data concerning sub Saharan Africa (SSA). The clinical picture in this context may reflect both difficult access to care and possible ethnic/geographic specificities. The impact on the growing public health problem of infertility in Africa is unknown. Dopamine agonists are the gold standard treatment of hyperprolactinemia, although associated with various adverse effects. Cabergoline is generally preferred due to better compliance, limited side effects and good therapeutic response [4, 5] . Bromocriptine widely and satisfactorily used in a context of limited availability of cabergoline [6] . Whether the more expensive cabergoline would be effective and potentially cost saving has not been reported. We sought to describe clinical manifestations of hyperprolactinemia and response to cabergoline in a SSA setting, as improving on the diagnosis and management for hyperprolactinemia is likely to improve infertility care in this context.
Methods
We conducted a cross-sectional study over a period of 2 years. We 
Conclusion
Our study suggests that serum prolactin levels should be measured in all patients consulting for infertility or for menstrual cycle disorders, and that cabergoline yields an excellent therapeutic response in a short period of time and may thus be cost saving in sub Saharan context despite its unit price.
What is known about this topic
 Hyperprolactinemia is a main cause of infertility even in men and women;
 Prolactinomas are the main causes of hyperprolactinemia;
 There is a good therapeutic response to cabergoline.
What this study adds
 The study highlights the early therapeutic response and in a short time of cabergoline;
 Microprolactinomas is most frequent in our context;
 Hyperprolactinemia is also a frequent cause of infertility in our context.
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